Contributions
Abstract: P557
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 21 Imaging
Purpose: Linear measures such as corpus callosum index (CCI), normalised corpus callosum area (nCCA) and width of the third ventricle (W3V) could be a good alternative to global brain volumetric measures in clinical practice for assessing the neurodegenerative component of multiple sclerosis (MS). Our objective is to test this hypothesis by comparing linear and volumetric measures.
Materials and methods: Fifty-eight patients with a clinically isolated syndrome (CIS) (group 1), 48 MS patients treated with interferon β (group 2) and 26 treated with natalizumab (group 3) underwent a brain MRI (58 on 3T and 74 on 1.5T) at two time points (baseline and one year). Baseline and follow-up CCI, nCCA and W3V measurements were obtained by two raters using Jim v.6.0. Volumetric tools (SIENA/x and Freesurfer) were used to calculate normalised brain volume (NBV), brain parenchymal fraction (BPF), annualised percentage of brain volume change (aPBVC), corpus callosum volume (CCvol), volume of the lateral ventricles (LVV) and volume of the third ventricle (3VV). Statistical analyses were performed with SPSS v.13.
Results: Intra-class correlation coefficient analyses showed very good intra-rater/inter-rater reliability for CCI (ICC=0.928/0.926), nCCA (ICC=0.927/0.9) and W3V (ICC=0.9/0.947). As a validation of nCCA and W3V, we used CCvol and 3VV respectively which showed a very good correlation (r=0.847,p< 0.01; r=0.834, p< 0.01). W3V correlations with NBV/BPF were weak/moderate in group 1 (r=-0.369, r=-0.463; p< 0.05), moderate/weak in group 2 (r=-0.569, r=-0.357; p< 0.05) and moderate/strong in group 3 (r=-0.540, r=-0.608; p< 0.05). CCI correlations with NBV/BPF were not significant/weak in group 1 (r=0.123 (ns), r=0.267 (p< 0.05), moderate/weak in group 2 (r=0.561, r=0.319; p< 0.05) and moderate/strong in group 3 (r=0.552, r=0.672; p< 0.05). nCCA correlations with NBV/BPF were not significant in group 1(r=-0.115, r=0.092), weak in group 2 (r=0.384, r=0.303; p< 0.05) and moderate/strong in group 3 (r=0.581, r=0.668; p< 0.05).
Conclusion: Linear measures are highly reproducible, but only two of them had a strong correlation with their equivalent volumetric measure. Correlations between linear and whole brain volume measures were stronger in patients with more advanced disease.
Disclosure:
S. Cappelle has nothing to disclose.
M. Alberich has nothing to disclose.
R. Alyafeai has recieved MSIF fellowship grant.
A. Vidal-Jordana has received honoraria as speaker and/or for participation in Advisory Boards from Novartis, Roche, Sanofi-Genzyme, and Biogen.
D. Pareto has received speaking honoraria from Novartis and Genzyme.
A. Rovira serves on scientific advisory boards for Biogen Idec, Novartis, Genzyme, and OLEA Medical, and on the editorial board of the American Journal of Neuroradiology and Neuroradiology, has received speaker honoraria from Bayer, Genzyme, Sanofi-Aventis, Bracco, Merck-Serono, Teva Pharmaceutical Industries Ltd, Stendhal, Novartis and Biogen Idec, and has research agreements with Siemens AG.
C. Auger has received speaking honoraria from Novartis and Stendhal
M. Tintoré received speaking honoraria and travel expenses for scientific meetings in the past with Amirall, Bayer, Biogen Idec, Genzyme, Merck Serono, Novartis, Sanofi-Aventis, Roche and Teva.
J.Sastre-Garriga has received honoraria for speaking or participation in advisory boards in the last twelve months from Celgene, TEVA, Novartis, Merck, Genzyme and Biogen.
Abstract: P557
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 21 Imaging
Purpose: Linear measures such as corpus callosum index (CCI), normalised corpus callosum area (nCCA) and width of the third ventricle (W3V) could be a good alternative to global brain volumetric measures in clinical practice for assessing the neurodegenerative component of multiple sclerosis (MS). Our objective is to test this hypothesis by comparing linear and volumetric measures.
Materials and methods: Fifty-eight patients with a clinically isolated syndrome (CIS) (group 1), 48 MS patients treated with interferon β (group 2) and 26 treated with natalizumab (group 3) underwent a brain MRI (58 on 3T and 74 on 1.5T) at two time points (baseline and one year). Baseline and follow-up CCI, nCCA and W3V measurements were obtained by two raters using Jim v.6.0. Volumetric tools (SIENA/x and Freesurfer) were used to calculate normalised brain volume (NBV), brain parenchymal fraction (BPF), annualised percentage of brain volume change (aPBVC), corpus callosum volume (CCvol), volume of the lateral ventricles (LVV) and volume of the third ventricle (3VV). Statistical analyses were performed with SPSS v.13.
Results: Intra-class correlation coefficient analyses showed very good intra-rater/inter-rater reliability for CCI (ICC=0.928/0.926), nCCA (ICC=0.927/0.9) and W3V (ICC=0.9/0.947). As a validation of nCCA and W3V, we used CCvol and 3VV respectively which showed a very good correlation (r=0.847,p< 0.01; r=0.834, p< 0.01). W3V correlations with NBV/BPF were weak/moderate in group 1 (r=-0.369, r=-0.463; p< 0.05), moderate/weak in group 2 (r=-0.569, r=-0.357; p< 0.05) and moderate/strong in group 3 (r=-0.540, r=-0.608; p< 0.05). CCI correlations with NBV/BPF were not significant/weak in group 1 (r=0.123 (ns), r=0.267 (p< 0.05), moderate/weak in group 2 (r=0.561, r=0.319; p< 0.05) and moderate/strong in group 3 (r=0.552, r=0.672; p< 0.05). nCCA correlations with NBV/BPF were not significant in group 1(r=-0.115, r=0.092), weak in group 2 (r=0.384, r=0.303; p< 0.05) and moderate/strong in group 3 (r=0.581, r=0.668; p< 0.05).
Conclusion: Linear measures are highly reproducible, but only two of them had a strong correlation with their equivalent volumetric measure. Correlations between linear and whole brain volume measures were stronger in patients with more advanced disease.
Disclosure:
S. Cappelle has nothing to disclose.
M. Alberich has nothing to disclose.
R. Alyafeai has recieved MSIF fellowship grant.
A. Vidal-Jordana has received honoraria as speaker and/or for participation in Advisory Boards from Novartis, Roche, Sanofi-Genzyme, and Biogen.
D. Pareto has received speaking honoraria from Novartis and Genzyme.
A. Rovira serves on scientific advisory boards for Biogen Idec, Novartis, Genzyme, and OLEA Medical, and on the editorial board of the American Journal of Neuroradiology and Neuroradiology, has received speaker honoraria from Bayer, Genzyme, Sanofi-Aventis, Bracco, Merck-Serono, Teva Pharmaceutical Industries Ltd, Stendhal, Novartis and Biogen Idec, and has research agreements with Siemens AG.
C. Auger has received speaking honoraria from Novartis and Stendhal
M. Tintoré received speaking honoraria and travel expenses for scientific meetings in the past with Amirall, Bayer, Biogen Idec, Genzyme, Merck Serono, Novartis, Sanofi-Aventis, Roche and Teva.
J.Sastre-Garriga has received honoraria for speaking or participation in advisory boards in the last twelve months from Celgene, TEVA, Novartis, Merck, Genzyme and Biogen.